8-K/AOther Events

BIOGEN INC. 8-K/A Report (Nov 25, 2003)

Filed November 25, 2003For Securities:BIIB

Summary

This 8-K/A filing by Biogen Inc. (BIIB) on November 25, 2003, serves as an amendment to a previous Form 8-K filed on November 21, 2003. The primary purpose of this amendment is to correct the date referenced in the disclosure regarding the change in its certifying accountant. Specifically, the period under review for disagreements or reportable events with its former accountant, KPMG LLP, has been updated from September 30, 2003, to November 17, 2003. This amendment ensures the accuracy of the reporting period related to the change in auditors. For investors, this filing confirms that there were no material disagreements or reportable events with KPMG through November 17, 2003. The company has provided a letter from KPMG addressing this disclosure, which is attached as an exhibit, reinforcing transparency regarding the auditor change.

Key Highlights

  • 1Amendment to a previous 8-K filing regarding the change in independent accountant.
  • 2Corrects the termination date of the accountant relationship from September 30, 2003, to November 17, 2003.
  • 3Confirms no disagreements on accounting principles, practices, disclosures, or auditing procedures with KPMG through November 17, 2003.
  • 4No 'reportable events' occurred with KPMG during the specified periods (fiscal years 2001, 2002, and interim period to November 17, 2003).
  • 5Includes a letter from KPMG LLP as Exhibit 16.2, confirming the auditor's perspective on the disclosure.
  • 6The filing aims to ensure accurate and timely reporting of changes in independent auditors as per SEC regulations.

Frequently Asked Questions

This filing is an amendment to a previous 8-K to correct the date associated with the change in Biogen's certifying accountant. The period reviewed for any disagreements or reportable events with the former accountant, KPMG, was updated from September 30, 2003, to November 17, 2003.

No, the filing explicitly states that through November 17, 2003, there were no disagreements with KPMG on any matter of accounting principles, practices, financial statement disclosure, or auditing scope or procedure.

'Reportable events' refer to specific situations outlined by the SEC (Item 304(a)(1)(v) of Regulation S-K) that must be disclosed when a company changes its independent accountant. These can include bankruptcies, adverse opinions, or disagreements. The filing confirms there were no such reportable events with KPMG.

KPMG's letter, attached as Exhibit 16.2, provides their perspective on the disclosures made in the 8-K regarding the auditor change. It serves to confirm the accuracy of Biogen's statements from the accountant's viewpoint, enhancing transparency for investors.